Date:3/26/2009

rights - 715 3,918 5,860 --- --- ----- ----- Net loss $(56,940) $(60,020) $(184,339) $(138,826) ======== ======== ========= ========= Net loss per share, basic and diluted $(2.04) $(2.53) $(7.19) $(10.04) ====== ====== ====== ======= Weighted-average common shares used in computing net loss per share, basic and diluted 27,948 23,694 25,646 13,829 ====== ====== ====== ====== JAZZ PHARMACEUTICALS, INC. SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended December Year Ended 31, December 31, --------------- ------------- 2008 2007 2008 2007 ---- ---- ---- ---- Xyrem $15,823 $11,120 $53,803 $39,018 Luvox CR 3,057 - 5,728 - Antizol (1) - 3,740 5,106 14,153 Cystadane (2) - - - 365 --- --- --- --- Total $18,880 $14,860 $64,637 $53,536 ======= ======= =====
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia